Clinical trials: Therapy Related Neoplasms
HCC, Hepatitis B Virus Related Hepatocellular Carcinoma
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
- Conditions
- HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT06617000
- Testing
- SCG101
- Where
- 7 sites in China
- Volunteers
- 38 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Carcinoid Syndrome
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).
- Trial name
- RELAX (NCT03223428)
- Testing
- Xermelo
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- TerSera Therapeutics LLC
D842-related Mutant GIST
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.
- Trial name
- NCT01243346
- Testing
- Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Breast Cancer
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
This was a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in participants with hormone receptor-positive early breast cancer who…
- Trial name
- AMEERA-6 (NCT05128773)
- Testing
- Amcenestrant, Tamoxifen
- Where
- 2 sites in Chile, China
- Volunteers
- 3 people
- Sponsor
- Sanofi
Cancer, Solid Tumor
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.
- Trial name
- NCT01017731
- Testing
- IMC-1121B, Moxifloxacin, Diphenhydramine
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Lymphoma, Non-Hodgkin, HIV Infections
Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma
The purpose of this study is to see if it is safe and effective to use gene therapy to treat non-Hodgkin's lymphoma (NHL) in HIV-positive patients. Stem cell transplantation is a procedure used to treat NHL.
- Trial name
- NCT00002221
- Testing
- Peripheral blood stem cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ribozyome
Myelodysplastic Syndromes (MDS)
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Alvocidib, a cyclin-dependent kinase 9 (CDK 9) inhibitor, in time-sequential therapy demonstrated significant clinical activity in secondary AML patients with prior MDS.
- Trial name
- NCT03593915
- Testing
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sumitomo Pharma America, Inc.
Ovarian Neoplasms, Peritoneal Neoplasms
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01846611
- Testing
- Trabectedin, DOXIL, Dexamethasone
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 581 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07216443
- Testing
- Orca-T
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Orca Biosystems, Inc.
Non-Small Cell Lung Cancer
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor…
- Trial name
- NCT05882734
- Testing
- M1774, Cemiplimab
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
- Trial name
- Orca-T (NCT05316701)
- Testing
- Orca-T, Standard-of-Care
- Where
- 19 sites in United States
- Volunteers
- 187 people
- Sponsor
- Orca Biosystems, Inc.
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901328
- Testing
- CB-5945
- Volunteers
- 49 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Breast Cancer
Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)
Patients are eligible for inclusion in this NIS if they have taken anastrozole either upfront or following two to three years of tamoxifen treatment ("switch") for at least three and not more than six months prior to offering an…
- Trial name
- COMPACT (NCT00857012)
- Where
- 383 sites in Germany
- Volunteers
- 2,313 people
- Sponsor
- AstraZeneca
Gynaecomastia, Prostate Cancer
Casodex - Nolvadex Combination
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex.
- Trial name
- NCT00637871
- Testing
- Casodex, Tamoxifen
- Sponsor
- AstraZeneca
Cancer-related Fatigue
Methylphenidate Treatment of Cancer-Related Fatigue
The purpose of this randomized controlled clinical trial is to investigate the efficacy and safety of methylphenidate in patients with fatigue caused by cancer.
- Trial name
- EMF (NCT00758407)
- Testing
- Methylphenidate hydrochloride
- Where
- 6 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Biliary Tract Cancer
A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients
This is a multi-center, retrospective, observational study of patients receiving first-line systemic therapy as routine clinical care for unresectable BTC in Japan.
- Trial name
- ARCBile (NCT07101874)
- Where
- 22 sites in Japan
- Volunteers
- 729 people
- Sponsor
- AstraZeneca
Malignant Carcinoid Syndrome
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with…
- Trial name
- NCT00092287
- Testing
- lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ipsen
Postoperative Stage II/III Colon Cancer
Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer
The purpose of this study is to evaluate the efficacy and safety of ART-123 for the prevention of cancer treatment related symptoms in patients with postoperative stage II / III colon cancer.
- Trial name
- NCT02792842
- Testing
- ART-123 (3-day ART), ART-123 (1-day ART)
- Where
- 2 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
Anemia, Neoplasms
A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia
The purpose of the study is to evaluate the safety of epoetin alfa in patients with cancer who have chemotherapy-related anemia.
- Trial name
- NCT01394991
- Testing
- Epoetin alfa 450 IU/kg once a week, Epoetin alfa 150 IU/kg 3 times a week, Epoetin alfa 450 IU/kg once a week (QW)
- Volunteers
- 504 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.